Imperial College London
Alternate

ProfessorRobinShattock

Faculty of Medicine, Department of Infectious Disease

Chair in Mucosal Infection and Immunity
 
 
 
//

Contact

 

+44 (0)20 7594 5206r.shattock

 
 
//

Location

 

453Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sandbrink:2020:10.3389/fimmu.2020.608460,
author = {Sandbrink, JB and Shattock, RJ},
doi = {10.3389/fimmu.2020.608460},
journal = {Frontiers in Immunology},
pages = {1--9},
title = {RNA vaccines: a suitable platform for tackling emerging pandemics?},
url = {http://dx.doi.org/10.3389/fimmu.2020.608460},
volume = {11},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The COVID-19 pandemic demonstrates the ongoing threat of pandemics caused by novel, previously unrecognized, or mutated pathogens with high transmissibility. Currently, vaccine development is too slow for vaccines to be used in the control of emerging pandemics. RNA-based vaccines might be suitable to meet this challenge. The use of an RNA-based delivery mechanism promises fast vaccine development, clinical approval, and production. The simplicity of in vitro transcription of mRNA suggests potential for fast, scalable, and low-cost manufacture. RNA vaccines are safe in theory and have shown acceptable tolerability in first clinical trials. Immunogenicity of SARS-CoV-2 mRNA vaccines in phase 1 trials looks promising, however induction of cellular immunity needs to be confirmed and optimized. Further optimization of RNA vaccine modification and formulation to this end is needed, which may also enable single injection regimens to be achievable. Self-amplifying RNA vaccines, which show high immunogenicity at low doses, might help to improve potency while keeping manufacturing costs low and speed high. With theoretical properties of RNA vaccines looking promising, their clinical efficacy is the key remaining question with regard to their suitability for tackling emerging pandemics. This question might be answered by ongoing efficacy trials of SARS-CoV-2 mRNA vaccines.
AU  - Sandbrink,JB
AU  - Shattock,RJ
DO  - 10.3389/fimmu.2020.608460
EP  - 9
PY  - 2020///
SN  - 1664-3224
SP  - 1
TI  - RNA vaccines: a suitable platform for tackling emerging pandemics?
T2  - Frontiers in Immunology
UR  - http://dx.doi.org/10.3389/fimmu.2020.608460
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000604609200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2020.608460/full
UR  - http://hdl.handle.net/10044/1/88431
VL  - 11
ER  -
Download